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Liposomes are self-assembling colloidal particles composed of a
lipid bilayer enclosing a fraction of the surrounding aqueous
medium (Lasic and Papahadjopoulos, 1995). Following their orig-
inal description more than 30 years ago (Bangham et al, 1965), the
prospect of their application to the arena of targeted drug delivery
was rapidly appreciated (Gregoriadis et al, 1974). However, such
conventional liposomes failed to fulfil their early promise, largely
as a result of rapid clearance by the reticulo-endothelial system
(RES), unpredictable patterns of extravasation and lack of long-
term physicochemical stability (Gabizon, 1994). The development
of pegylated liposomes in the last decade has rekindled interest in
the clinical application of liposomes in the treatment of cancer.
The lipid bilayer of pegylated liposomes contains glycolipid or
poly(ethylene glycol) (PEG)-derivatized lipid which furnishes a
steric barrier against interactions with plasma proteins, such as
opsonins and lipoproteins, and cell surface receptors. Con-
sequently, these pegylated liposomes evade the RES and remain in
the circulation for prolonged periods, thereby conferring on
entrapped agents the pharmacokinetic profile of the lipid carrier
rather than that of the free drug (Gabizon et al, 1994). Impressive
response rates to pegylated liposomal chemotherapeutic agents
have been obtained in mice bearing mouse mammary tumours and
human tumour xenografts (reviewed in Working et al, 1994). In
clinical trials, pegylated liposomes containing doxorubicin have
been shown to be active against AIDS-related Kaposi’s sarcoma,
with response rates in excess of either free doxorubicin or conven-
tional combination chemotherapy (Bogner et al, 1994; Harrison et
al, 1995; Goebel et al, 1996). Trials of liposomal chemotherapy in
patients with a variety of solid tumours are currently under way.
In addition to their use as a means of targeting cytotoxic
chemotherapy, pegylated liposomes offer a means of delivering a
variety of other therapeutic modalities to tumours. In order to
facilitate the rational integration of liposome technology into
current or novel therapeutic strategies, detailed knowledge of the
factors which govern liposome distribution to tumours will be
required. There is a considerable amount of data in the literature
examining the effect of liposomal composition on their pharmaco-
kinetics and biodistribution (Gabizon and Papahadjopoulos, 1988;
Gabizon et al, 1990; Klibanov et al, 1990). However, there is rela-
tively little known about the influence of tumour-related factors on
liposomal tumour targeting. Jain (1990) categorized the physiolog-
ical barriers limiting the delivery of macromolecules to tumours as
being due to heterogeneous blood flow, raised tumour interstitial
pressure and large transport distances in the tumour interstitium. It
is likely that these phenomena will play a role in the localization of
liposomes to tumours. However, since pegylated liposomes are
targeted to the tumour via the vasculature, tumour vascular volume
and blood flow rate are likely to be major determinants of lipo-
somal localization. There is evidence to suggest that in the early
stages of a tumour’s growth its vascular volume increases but, 
as growth continues, the fractional vascular volume decreases.
Similarly, there is evidence to support the notion that, as tumours
grow larger, necrotic areas begin to develop and the average blood
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(Menlo Park, CA, USA).perfusion rate decreases. These findings are supported by clinical
data derived from positron emission tomography which have
shown that blood flow in human breast cancers is reduced in
necrotic/seminecrotic areas and greater than normal in non-
necrotic regions (Beaney et al, 1984). The raised interstitial
pressure in tumours decreases the transvascular transport of
macromolecules. This effect would be expected to reduce extrava-
sation of liposomes in larger tumours, since the interstitial pressure
gradients are greater in large compared with small tumours (Jain
and Baxter, 1988). The effect of the large transport distances in the
tumour interstitium may be of relatively minor importance to lipo-
some drug delivery to tumours, since they remain confined to the
perivascular space after extravasation (Huang et al, 1992).
Subsequent leakage of liposomal contents allows their diffusion
throughout the tumour, the extent of which is likely to be governed
by the molecular mass of the entrapped substance as opposed to
that of the entire liposome.
As part of the process of improving the understanding of lipo-
somal localization to tumours, we have undertaken a study to eval-
uate the effect of tumour size on the uptake of 111In-DTPA-labelled
pegylated liposomes, and whether this correlates with the vascu-
larisation of the tumour.
MATERIALS AND METHODS
Tumour model
The animals used in this study were female nude mice of mixed
genetic background. They were bred under specific pathogen-free
conditions at the Imperial Cancer Research Fund Animal Breeding
Unit, South Mimms, Herts, UK. Subsequently, the animals were
housed in sterile filter-top cages on sterile bedding, and maintained
on an irradiated diet and autoclaved, acidified water (pH 2.8).
The human tumour cell line KB was originally established in cell
culture in 1954 from a male patient with a poorly differentiated
squamous cell cancer of the floor of mouth and tongue (Eagle, 1955).
Tumour cells were grown to confluence in vitro in RPMI-1640
medium containing 100 U ml–1 penicillin and 100 µ g ml–1 strepto-
mycin, supplemented with 10% fetal calf serum (FCS) (Gibco,
Paisley, UK) at 37° C in a humidified atmosphere of 5% CO2 in 
air. Tumour cells were harvested by incubating briefly with
trypsin/versene and a single cell suspension was prepared. Tumour
xenografts were set up by subcutaneous injection of 5× 106 tumour
cells in 0.1 ml of culture medium into the right flank of the mice. The
animals were used for experiment between 4 and 20 days after tumour
inoculation, at which time tumours of various sizes were available.
Liposome labelling with 111In-oxine
Diethylenetriaminepentaacetic acid (DTPA, Janssen Chimica,
Geel, Belgium) was entrapped by SEQUUS™ Pharmaceuticals,
Inc in a proprietary pegylated liposome matrix which included the
poly(ethylene glycol) methyl ether carbamate of distearoyl phos-
phatidylethanolamine. Liposomes were labelled by incubating 
2 ml of 111In oxine (Amersham International plc, Amersham, UK)
with 20 ml of DTPA-containing pegylated liposomes. Four
milligrams of ethylenediaminetetraacetic acid (EDTA) (BDH Ltd,
Poole, UK) was added to chelate any residual free 111In and
promote its prompt excretion after intravenous injection. Indium
entrapment was typically greater than 90%. It was assayed by
loading a 10 µ l sample onto a 20 ml Sephadex G50 column
(Pharmacia, Uppsala, Sweden). Thirty consecutive 1 ml fractions
were eluted with phosphate buffered saline and the activity of each
fraction was counted in a Canberra Packard Minaxi 5550 gamma
counter (Pangbourne, Berks, UK).
Determination of tumour uptake of radiolabelled
liposomes
KB tumour-bearing nude mice received an intravenous bolus
injection of 100 µ l of 111In-labelled pegylated liposomes,
containing 0.37–0.74 MBq (10–20 µ Ci) of activity, via a lateral
tail vein. Mice were killed by cardiac puncture and exsanguination
24 hours after the injection of pegylated liposomes. At this time
liposome uptake in the tumour is maximal in this model system
(Harrington et al, in press). The tumour was dissected out and the
radioactivity per gram of tumour and blood was determined by
counting pre-weighed tubes in a gamma counter. The variation of
liposome uptake with tumour weight was determined for 62 mice.
Determination of tumour vascular volume
The vascular volume of KB xenograft tumours of various sizes
was determined by a modification (Sands et al, 1985) of the
method of Song and Levitt (1970), using in vivo radiolabelling of
erythrocytes with technetium-99m (99mTc) rather than in vitro
labelling with chromium-51 (51Cr). Forty-three mice bearing 52
tumour xenografts were used. Nine mice had tumours implanted
bilaterally at an interval of 10 days and were used for experiment
15 days after the first tumour was implanted. The mice received 
an intravenous injection of 1.2 µ g stannous fluoride in 100 µ l of
saline (Amerscan, Amersham International), followed 30 minutes
later by 30 µ Ci of 99mTcO4. Precisely one hour after injection of the
radioactivity, the mice were killed by cervical dislocation. The
tumour and a small sample of blood were removed, weighed and
their  99mTc activity was measured in a gamma counter. The
following formula was used to calculate the vascular volume
(VV), measured in millilitres of blood per gram of tissue:
VV = 99mTc activity per gram of tissue/99mTc activity per gram
of blood
Correction of data for retained blood content
Even after killing by exsanguination, up to 30–40% of the
animals’ blood volume can remain in the circulation. Therefore, a
proportion of the measured level of radioactivity in the tumour
specimens may be attributed to 111In-DTPA-labelled pegylated
liposomes in the vascular compartment of the tumour. In an
attempt to correct for this blood-borne radioactivity, the mean
vascular volume for tumours in the size ranges < 0.01 g,
0.01–0.099 g, 0.1–0.499 g, 0.5–0.999 g and > 1.0 g were calcu-
lated and together with the measured blood radioactivity (%ID/g at
24 hours) for each individual mouse were used to give an estimate
of the amount of the measured radioactivity due to blood retained
in the tumour. Because it was not possible to measure the exact
amount of blood retained in the circulation following exsanguina-
tion, all calculations were based on the assumption that no blood
was removed from the circulation of the tumour. This is likely to
have led to overestimation of the contribution of blood-borne
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of the blood in the vascular compartment of the tumour was
subtracted from the measured weight of each tumour to yield a
corrected weight corresponding to the extravascular compartment
of the tumour. This correction for the weight of retained blood is
also likely to have been an overestimate for the same reason as
stated above. These two values (corrected radioactivity and
corrected weight) were used to calculate the corrected % ID/g. In
practice, these estimations made little difference to the corrected
%ID/g values that were obtained.
Measurement of intratumour distribution of
radiolabelled liposomes in tumours with macroscopic
central necrosis
Eighteen mice bearing KB xenograft tumours of median weight
1.10 g (range 0.45–3.28 g) received 100 µ l of 111In-DTPA-labelled
pegylated liposomes containing 10 µ Ci of radioactivity via intra-
venous injection into a lateral tail vein. The mice were killed 24
hours later by exsanguination and samples of blood and tumour
were removed for determination of their content of radioactivity.
The level of uptake of pegylated liposomes was measured for the
entire tumour as described above. Thereafter, the tumour was cut
into quarters and the macroscopically visible central necrotic core
was removed. The levels of radioactivity in the necrotic central
core and the tumour rim were then measured separately.
Histological analysis of tumour necrosis
Ten KB xenograft tumours of different sizes, ranging in weight
from 0.3 to 1.33 grams, were fixed in formal saline and embedded
in paraffin. Sections of 5 µ m thickness were cut and picked up on
slides coated with 0.1% poly-L-lysine (Sigma, Poole, UK), dried
overnight and stored at room temperature until use. Thereafter,
they were stained with haematoxylin and eosin.
Statistical analysis
The correlation between tumour weight and liposome uptake was
analysed by means of the Spearman’s rank correlation test and the
Pearson’s correlation coefficient after logarithmic transformation
of the data. The Spearman’s rank correlation test was also used to
assess the relationship between tumour weight and tumour
vascular volume. 95% confidence intervals were calculated for the
Spearman’s rank correlation coefficients (rs). For the 9 animals
with bilateral tumours, the Wilcoxon signed rank test was used to
evaluate the relationship between tissue weight and vascular
volume for the respective paired samples. The paired Student’s test
was used for the comparison between the radioactivity in the
central core and periphery of the 18 tumours with demonstrable
central necrosis. P values < 0.05 were considered significant.
RESULTS
Relationship between liposome uptake and tumour
weight
The mean uptake of 111In-labelled pegylated liposomes at 24 hours
was 7.2 ± 6.6% ID/g for the tumour specimens. The relationship
between tumour weight and tumour liposome uptake is shown in
Figure 1. These data represent values corrected for the estimated
contribution of retained blood to both the tumour uptake and
weight. A strong inverse correlation between tumour weight and
liposome uptake was observed using the Spearman’s rank correla-
tion test (rs = – 0.573 [95% CI = – 0.377 to – 0.720], t = 5.413, 
P < 0.001). The relative variance (coefficient of variation)
decreased with increasing tumour weight with liposome uptake for
tumours < 0.1 g, 0.1–1.0 g and > 1.0 g of 15.1 ± 10.8, 5.9 ± 2.2 and
3.0 ± 1.3% ID/g, respectively. The blood levels of radiolabelled
liposomes for animals with tumours of < 0.1 g, 0.1–1.0 g and 
> 1.0 g were 5.8 ± 2.8, 5.4 ± 3.1 and 6.3 ± 2.2% ID/g, respectively,
confirming that the observed inverse correlation between tumour
weight and liposome uptake was not due to higher blood liposome
levels in mice with smaller tumours. The statistical analysis was
repeated for the measured data uncorrected for the contribution of
blood to measured radioactivity and weight. This analysis yielded
virtually identical results (rs = – 0.622 [95% CI = – 0.441 to 
–0.754], t = 6.159, P < 0.001). In addition, analysis of the data
corrected for retained blood by the Pearson’s correlation coeffi-
cient demonstrated a significant inverse correlation between
tumour weight and liposome uptake (rs = – 0.555, P < 0.001).
Vascular volume measurements
An inverse correlation between tumour weight and tumour
vascular volume was also demonstrated, as shown in Figure 2
(Spearman’s rank correlation test rs = – 0.598 [95% CI = – 0.388 to
– 0.749], t = 5.282, P < 0.001). Analysis of the paired samples
showed that, for the 9 animals with bilateral tumours, the smaller
of the tumours had a significantly greater vascular volume (P =
0.02).
Variation of liposome uptake in tumour centre and
tumour rim
Tumour uptake was 3.5 ± 1.4% ID/g for the 18 whole tumour
specimens. After separation of the tumour rim from the tumour
centre the levels of liposome uptake were found to be 4.8 ± 1.7%
ID/g and 0.6 ± 0.4% ID/g for the tumour rim and tumour core,
respectively (P < 0.001). The ratio of uptake in the tumour rim
relative to the tumour core was 11.2 ± 6.4.
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Figure 1 Relationship between tumour weight and liposome uptake in KB
xenograft tumoursHistological demonstration of tumour necrosis
Areas of necrosis were demonstrated to a variable degree in all of
the tumours that were examined histologically. The extent of the
necrosis seemed to be related to the size of the tumour with small
tumours (0.3–0.75 g) composed largely of viable tumour tissue
and larger tumours (> 0.75 g) containing large confluent areas of
necrotic tissue interspersed with islands of viable cells (Figure 3).
No attempt was made to quantify the absolute volume of necrosis
within the individual tumours.
DISCUSSION
The development of pegylated liposomes represents a major
advance in the field of liposomally-targeted therapy for cancer.
Considerable research effort has gone into the optimisation of the
composition of liposomes in order to achieve maximal tumour
targeting (Gabizon and Papahadjopoulos, 1988; Gabizon et al,
1990; Klibanov et al 1990). However, the effect of tumour-related
factors on this process has not been explored in detail. We have
investigated the effect of the clinically relevant parameter, tumour
size, on the uptake of pegylated liposomes in a human tumour
xenograft model and have attempted to examine the relationship in
terms of tumour vascularity.
This study demonstrated selective targeting and accumulation of
111In-DTPA-labelled pegylated liposomes in a KB tumour xenograft
model. This is confirmed by the high levels of liposome uptake in
tumour. Furthermore, the tumour uptake of liposomes was shown
to vary inversely with tumour size. This effect was particularly
pronounced for tumours of < 0.1 g, in which 7 of 13 tumours
showed a tumour uptake of > 10% ID/g at 24 hours. None of 49
tumours greater than 0.1 g had a tumour uptake of > 10% ID/g.
Tumours in the intermediate size range, 0.1–1.0 g, showed an
intermediate level of uptake and larger tumours, > 1.0 g,  demon-
strated relatively low levels of liposome uptake. These findings are
paralleled by the inverse variation of tumour vascular volume with
tumour size, suggesting a possible association between tumour
vascularisation and liposome uptake. The high levels of liposome
uptake measured in small tumours may be explained by their high
vascular volumes comprised of relatively immature, leaky neovas-
culature. In addition, the interstitial pressure in small deposits may
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Figure 2 Relationship between tumour weight and tumour vascular volume
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Figure 3 Haematoxylin and eosin stained section of 1.33 g KB xenograft tumour (magnification × 100). The section is composed mainly of areas of necrosis
(N) with occasional islands of viable tumour tissue (T).688 KJ Harrington et al
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be lower than in larger deposits, irrespective of their state of vascu-
larization. The low levels of liposome uptake in large tumours
were likely to be due to a relatively low vascular volume,
reflecting areas of poor perfusion or even necrosis, coupled to a
high tumour interstitial pressure acting to limit liposomal extrava-
sation. This premise is supported by the finding that within an indi-
vidual tumour the central necrotic core showed significantly lower
levels of liposome uptake than the tumour rim.
A small number of tumours weighing < 0.1 g showed very low
levels of liposome uptake. The most likely explanation for this
apparently anomalous result might be that they have not developed
an adequate vascular supply, an hypothesis which is supported by
the low vascular volumes seen for some of the very small tumours.
These findings have important implications for the application
of liposomal drug delivery strategies to the clinical situation. The
high levels of uptake in the majority of small tumours suggest that
liposomally-targeted agents (cytotoxic drugs, radiosensitizers or
radiopharmaceuticals) would achieve effective therapeutic
concentrations in well-vascularized small and intermediate-sized
tumour deposits. This would translate to a clinical situation in
which small and medium-sized primary or metastatic lesions were
being treated and supports the notion that pegylated liposomal
drug entrapment offers a potential therapeutic advantage. Small,
inadequately vascularized, lesions would not be targeted effec-
tively by liposomal agents. However, these lesions would also tend
to be resistant to conventional, free cytotoxic drugs by virtue of
their poor blood supply. The relatively low levels of liposome
deposition in large tumour masses suggest that, in the clinically
analogous situation of locally advanced cancer, the therapeutic
advantage accruing from liposomal drug delivery might be less
favourable. However, the treatment of large, poorly-vascularized,
locally advanced tumours represents a major challenge in clinical
oncology and such tumours are infrequently controlled by conven-
tional chemotherapy. Current strategies for treating advanced
tumours involve delivering multiple cycles of cytotoxic chemo-
therapy over a period of many weeks in an attempt to reduce 
the tumour mass and its interstitial pressure and increase tumour
blood flow. The use of similar scheduling for liposomally-targeted
strategies would exploit the same, potentially advantageous mech-
anisms and therefore preserve the therapeutic advantages of lipo-
somal delivery. Alternatively, the use of vasoactive agents, such as
Tumour Necrosis Factor, or external beam radiotherapy, both of
which have been shown to increase the uptake of monoclonal anti-
bodies into tumours (Kalofonos et al, 1990; Rowlinson-Busza et al
1995), may be able to increase liposome deposition in large
tumours. Such approaches would certainly be worthy of further
study.
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